A double-blind, placebo-controlled study of the effect of a TNFα a inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with mild cognitive impairment due to Alzheimer's disease-intermediate likelihood

Trial Profile

A double-blind, placebo-controlled study of the effect of a TNFα a inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with mild cognitive impairment due to Alzheimer's disease-intermediate likelihood

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Etanercept (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Therapeutic Use
  • Acronyms INMiND02
  • Most Recent Events

    • 02 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.
    • 02 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top